TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics has announced successful independent validation of its ARG-007 compound in a preclinical study using a rat model of ischemic stroke. The study confirmed that a dose of 325 nmol/kg significantly reduced infarct volume by 47.3%, indicating a strong neuroprotective effect within a specific therapeutic window. These findings, along with previous clinical trial data, will guide future clinical development and dosing strategies for ARG-007 in treating acute ischemic stroke.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other neurological conditions.
Average Trading Volume: 588,668
Technical Sentiment Signal: Sell
Current Market Cap: A$28.9M
For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.